$-0.15
(Market cap
$492 Mln
Recently Viewed
Clear AllMarket cap
$492 Mln
Revenue (TTM)
$100 Mln
P/E Ratio
--
P/B Ratio
25.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-16.9
Debt to Equity
3.7
Book Value
$0.6
EPS
$-0.7
Face value
--
Shares outstanding
33,666,948
CFO
$-127.78 Mln
EBITDA
$-126.04 Mln
Net Profit
$-201.16 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neuropace Inc (NPCE)
| -5.1 | 4.4 | -13.6 | 32.0 | 42.2 | -- | -- |
|
BSE Sensex*
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Neuropace Inc (NPCE)
| 38.0 | 8.5 | 591.9 | -85.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neuropace Inc (NPCE)
|
14.7 | 491.5 | 100.0 | -21.5 | -15.3 | -158.7 | -- | 25.9 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 277.0 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 38.0 | 5,592.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.3 | |
| 119.5 | 6,777.2 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 81.4 | 4,954.3 | 1,541.6 | 233.6 | 21.6 | 21.4 | 22.3 | 4.5 | |
| 178.3 | 9,592.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.8 | 12.9 | |
| 329.5 | 12,945.1 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.8 | 9.1 | |
| 119.8 | 6,634.7 | 738.3 | 48.9 | 11.4 | 2.4 | 137 | 3.2 | |
| 33.1 | 13,926.0 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.8 | 2.6 |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant... focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. Address: 455 North Bernardo Avenue, Mountain View, CA, United States, 94043 Read more
Chief Medical Officer
Dr. Martha J. Morrell
Chief Medical Officer
Dr. Martha J. Morrell
Headquarters
Mountain View, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Neuropace Inc (NPCE) is $14.65 (NASDAQ) as of 09-Apr-2026 16:00 EDT. Neuropace Inc (NPCE) has given a return of 42.15% in the last 3 years.
Since, TTM earnings of Neuropace Inc (NPCE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-23.54
|
26.55
|
|
2024
|
-12.33
|
41.78
|
|
2023
|
-8.11
|
12.95
|
|
2022
|
-0.79
|
1.06
|
|
2021
|
-6.75
|
3.31
|
The 52-week high and low of Neuropace Inc (NPCE) are Rs 18.98 and Rs 7.56 as of 10-Apr-2026.
Neuropace Inc (NPCE) has a market capitalisation of $ 492 Mln as on 07-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Neuropace Inc (NPCE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.